A Long Term Follow-up Study to Evaluate the Safety of RetinoStat in Patients With Age-Related Macular Degeneration
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2018
Price : $35 *
At a glance
- Drugs Angiostatin-endostatin gene therapy Oxford BioMedica (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Sponsors Oxford BioMedica
- 16 Oct 2018 Planned number of patients changed from 21 to 18.
- 16 Oct 2018 Planned End Date changed from 1 Nov 2027 to 1 Mar 2029.
- 16 Oct 2018 Planned primary completion date changed from 1 Nov 2027 to 1 Mar 2029.